Citations

Clear

299 citation(s) found for "Solomon, B".

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
Masri, Ahmad , Cappelli, Francesco , Davis, Margot K., Fontana, Marianna , Gillmore, Julian D. , Hanna, Mazen, Solomon, Scott D. , Sperry, Brett W. , Waddington-Cruz, Márcia, Kristen, Arnt V., Falk, Rodney H. , Nativi-Nicolau, José , Viney, Nicholas J. , Yang, Qingqing , Chen, Jersey , Maurer, Mathew S. , Garcia-Pavia, Pablo , Gillmore, Julian D , Obici, Laura , Solomon, Scott David , Sperry, Brett W , Tahara, Nobuhiro , Waddington-Cruz, Márcia , Falk, Rodney H , Shah, Sanjiv J , Nativi-Nicolau, Jose , Tsimikas, Sotirios , Maurer, Mathew S , Cappelli, Francesco , Fontana, Marianna , Hanna, Mazen , Obici, Laura , Waddington‐Cruz, Márcia , Kristen, Arnt V.

Mayo Clinic

Circulation: Heart Failure | May 9, 2026 | Volume: 19 | Issue: 6 | Pages: No page available

10.1161/circheartfailure.126.014205 | PMID 42104840 Get It

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand–conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR. METHODS: CARDIO-TTRansform is a Phase 3, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of eplontersen in transthyretin amyloidosis with cardiomyopathy. Key inclusion criteria include histological evidence of amyloid deposits or grade 2 to 3 cardiac uptake on cardiac scintigraphy in the absence of plasma cell dyscrasia, New York Heart Association class I–III, and end-diastolic interventricular septum thickness >12 millimeters. Participants were randomized 1:1 to receive eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks for up to 140 weeks, followed by a 20-week post-treatment evaluation period or open-label extension. Participants received locally available standard of care, including unrestricted use of TTR stabilizers. The primary end point is a composite of cardiovascular mortality and recurrent clinical cardiovascular events through 140 weeks. Secondary end points, in order of testing hierarchy, include changes from baseline in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary score, recurrent cardiovascular events, all-cause mortality, the primary end point in the patient subgroup receiving stabilizers at baseline, and cardiovascular mortality. Echocardiography was performed in all participants, with cardiovascular magnetic resonance imaging and technetium scintigraphy in a subset. CONCLUSIONS: CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04136171. URL: http://ClinicalTrialsRegister.eu ; Unique identifier: EudraCT number 2019-002835-27.
AAPM Task Group Report 336: Quality assurance for 3D printing in medical imaging and radiation therapy applications
Leng, Shuai, Craft, D. , Angel, Erin , Howell, Rebecca M., Jesseph, F., Kiarashi, Nooshin, Lewis, John H., Lo, Joseph, Markovic, Alex, McGee, Kiaran P. , Prah, D.E. , Rasmussen, Karl H., Rong, Yi, Schaefer, Kyle E., Solomon, Justin B., Leng, Shuai , Howell, Rebecca M. , Ionita, Ciprian N. , Lewis, John Henry , Lo, Joseph Yuan-Chieh , Solomon, Justin , Wake, Nicole

Mayo Clinic

Medical Physics | April 29, 2026 | Volume: 53 | Issue: 5 | Pages: No page available

10.1002/mp.70446 Get It

Abstract Additive manufacturing (AM), commonly referred to as 3D printing, has been broadly used in the field of medical imaging and radiotherapy. In medical imaging applications, patient‐specific anatomic models have been used to aid in preoperative planning, patient communication, imaging technique assessment and optimization, and medical education. Within the field of radiation therapy, 3D printing finds significance in fabricating patient‐specific immobilization devices, custom bolus devices, anthropomorphic phantoms, brachytherapy devices, and electron therapy devices. Consistent with standard medical physics practices there is a need to establish quality assurance and quality control (QA/QC) protocols, tolerances, and testing frequencies. The diversity of 3D printing technologies and products poses challenges for medical adoption and thus requires guidelines in workflow standardization and establishment of testing procedures. This report is centered around providing comprehensive vendor‐neutral implementation guidelines and recommendations for QC and QA processes. The scope of this report encompasses diverse requirements within medical imaging and radiation therapy settings, serving both clinical and research purposes. Brief overview of 3D printing technology, common materials, and potential clinical applications is provided. QA team, infrastructure, measurement techniques and challenges are discussed. QA processes for each step in 3D printing are discussed in great detail and baseline and action limits are recommended. This report also touched on regulatory considerations. Key recommendations are summarized at the end of the report.
Presacral tumours: international consensus on diagnosis and management
Perry, William R G, Brown, KF, Burns, Elaine, Frizelle, Frank, Glover, Thomas , Glyn, Tamara , Heriot, Alexander, Merchea, Amit , Quyn, Aaron, Sagar, P., Thomas, Gregory, Tiernan, Jim , Turner, Gregory A., Warrier, Satish, Wood, Verity, Group, the Presacral Tumour Working, Cerkaukaite, Dovile, Khan, Ayman , Koneru, S R, Vu, J, Jenkins, John T. , Dozois, E, Heriot, Alexander G. , Perry, William , Perry, William R , Heriot, Alexander , Merchea, Amit , Sagar, Peter , Solomon, Michael J , Burns, Elaine Marie , Denost, Quentin , Graham, Rondell P. , Solomon, Michael J. , Turner, Gregory A, Wood, Verity , Koneru, Sireesha, Litchinko, Alexis , Dozois, Eric J.

Mayo Clinic

British Journal of Surgery | April 28, 2026 | Volume: 113 | Issue: 5 | Pages: No page available

10.1093/bjs/znag053 | PMID 42049258 Get It

Abstract Background Presacral tumours are rare and heterogeneous lesions arising within a complex anatomical space, resulting in variability in diagnosis and management. Increasing incidental detection and evolving surgical and oncological strategies have highlighted the need for contemporary guidance. The aim of this study was to establish an international expert consensus on the optimal diagnosis and management of presacral tumours. Methods An international panel of colorectal surgeons from high-volume units was convened. Evidence- and practice-based statements were developed after domain-based literature reviews and refined through five online and two in-person meetings. Consensus was achieved using a modified Delphi process with anonymous voting. Results In total, 16 colorectal surgeons participated in the study. Ten domains were identified resulting in the development of 22 statements based on expert opinion and retrospective studies. After two rounds, unanimous (100%) agreement was achieved for all statements. High-resolution MRI with structured synoptic reporting is endorsed as central to risk stratification. Selective image-guided transperineal or parasacral biopsy is recommended for high-risk lesions where histology would alter management. Complete surgical resection is defined as the operative goal, with approach tailored to tumour biology and anatomy; minimally invasive surgery is considered appropriate in selected cases. Non-operative surveillance is supported for carefully selected asymptomatic, low-risk cystic lesions. Postoperative surveillance is recommended in a risk-adapted manner according to histopathology and margin status. Conclusion This international consensus provides a pragmatic, risk-stratified framework for the multidisciplinary diagnosis and management of presacral tumours. These recommendations aim to reduce practice variation, support decision-making in specialized centres, and inform future prospective collaborative research.
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
Stepan, Lara , Ansari, Sahar , Abramson, Jeremy, Okal, Abood, Dell’Aringa, Justine, Thompson, Ethan G., Crotta, Alessandro, Chow, Victor A. , Kamdar, Manali , Solomon, Scott R. , Johnston, Patrick B. , Glaß, Bertram , Mutsaers, Pim , Arnason, Jon, Mielke, Stephan , Hernandez-Ilizaliturri, Francisco, Bachanová, Veronika , Chabon, Jacob J. , Alizadeh, Ash A. , Peiser, Leanne, Abramson, Jeremy S. , Abramson, Jeremy S , Shadman, Mazyar , Izutsu, Koji , Bachanova, Veronika , Ibrahimi, Sami , Kurtz, David M , Alizadeh, Ash A , Peiser, Leanne , Kamdar, Manali , Mielke, Stephan , Ansari, Sahar, Arnason, Jon , Shadman, Mazyar , Hernandez‐Ilizaliturri, Francisco J. , Izutsu, Koji , Ibrahimi, Sami , Kurtz, David M.

Mayo Clinic

Journal of Clinical Oncology | April 27, 2026 | Volume: 44 | Issue: 19 | Pages: 1767-1773

10.1200/jco-25-03051 | PMID 42044466 Get It

We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351 ) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD] neg ) predicted longer event-free survival (EFS) at all time points in both arms, with significantly more liso-cel–treated patients achieving MRD neg . Liso-cel demonstrated superior outcomes versus ASCT, including longer EFS, progression-free survival (PFS), and duration of response among patients in complete response (CR) and MRD neg . ctDNA re-emergence in patients with CR after ASCT confirmed its potential in predicting relapse. MRD neg remained significantly associated with EFS after adjusting for positron emission tomography (PET) response, while interaction testing revealed a significant interaction between PET status and treatment arm for EFS. Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.
Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals
Ni, Zhanmo , Zhong, Jun , McKean, David, Antwi, Samuel O. , Bracci, Paige M., Du, Mengmeng, Gallinger, Steven, Genkinger, Jeanine, Haiman, Christopher A, Hassan, Manal, Huff, Chad , Kooperberg, Charles, Kastrinos, Fay , LeMarchand, Loic, Lee, WP, Oberg, Ann L. , Park, Margaret A. , Permuth, Jennifer B., Risch, Harvey A., Scheet, Paul , Schwartz, Ann, Shu, Xie, Wolpin, Brian M. , Albanes, Demetrius, Andreotti, Gabriella , Beane-Freeman, Laura, Berndt, Sonja I, Brennan, Paul, Buring, Julie E, Cabrera, Natalia, Campa, Daniele, Chanock, Stephen J, Chung, Charles C., Eliassen, A Heather, Gaziano, J. Michael, Giles, G G, Giovannucci, Edward L, Goggins, Michael, Goodman, Phyllis J. , Hicks, Belynda, Hutchinson, Amy , Jones , Katzke, Verena, Kogevinas, Manolis, Kurtz, Robert C. , Laheru, Daniel, Lee, I, Milne, Roger, Mucci, Lorelei, Patel, Alpa V, Peruchet, Laia, Peters, Ulrike, Porta, Miquel, Rabe, Kari G. , Real, Francisco X, Ricceri, Fulvio, Rothman, Nathaniel, Sesso, Howard D. , Setiawan, Veronica W, Debra, Silverman, Southey, M C, Stampfer, M I, Um, Caroline, Visvanathan, Kala, Wentzensen, Nicolas, Willett, Walter C, Kraft, Peter, Visvanathan, Kala , Zhong, Jun , Zheng, Wei , Canzian, Federico , Malats, Nuria , Duggal, Priya , Klein, Alison P , Chaffee, Kari G. , Antwi, Samuel O , Visvanathan, Kala , Vergara, Candelaria , McKean, David , Connelly, Katelyn E. , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng, Genkinger, Jeanine M. , Haiman, Christopher A. , Hung, Rayjean J. , Kooperberg, Charles , Lynch, Shannon M. , Moore, Steven C. , Permuth, Jennifer B. , Risch, Harvey A., Schwartz, Ann, Stolzenberg‐Solomon, Rachael Z. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Berndt, Sonja I. , Brennan, Paul, Buring, Julie E. , Cabrera-Castro, Natalia , Canzian, Federico , Chanock, Stephen Jacob , Chen, Yu , Gaziano, J. Michael , Giovannucci, Edward L. , Goggins, Michael , Hicks, Belynda , Katzke, Verena , Kogevinas, Manolis , Laheru, Daniel A. , Malats, Núria , Milne, Roger, Mucci, Lorelei A. , Neale, Rachel Ε. , Orlow, Irene , Peruchet‐Noray, Laia , Peters, Ulrike , Real, Francisco X. , Ricceri, Fulvio , Rothman, Nathaniel , Setiawan, Veronica Wendy , Silverman, Debra T. , Southey, Melissa C , Stampfer, Meir J. , Tobias, Geoffrey S. , Um, Caroline Y. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yu, Kai , Duggal, Priya , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.21.26351329 | PMID 42078392 Get It

Abstract Pancreatic cancer disproportionately affects Black individuals in the United States, but they have limited representation in genetic studies of pancreatic ductal adenocarcinoma (PDAC). To address this gap, we performed admixture mapping and genome-wide association analysis (GWAS) in genetically inferred African ancestry individuals (1,030 cases and 889 controls). Admixture mapping identified three regions with a significantly higher proportion of African ancestry in cases compared to controls (5q33.3, 10p1, 22q12.3). GWAS identified a genome-wide significant association at 5p15.33 ( CLPTM1L , rs383009:T>C, T Allele Frequency=0.51, OR:1.45, P value=1.24×10 -8 ), a locus previously associated with PDAC. Known loci at 5p15.33, 7q32.3, 8q24.21 and 7q25.1 also replicated (P value <0.01). Multi-ancestral fine-mapping identified two potential causal SNPs (rs3830069 and rs2735940) at 5p15.33. Collectively these findings identified novel PDAC risk loci and expanded our understanding of this deadly cancer in underrepresented populations, emphasizing the multifactorial nature of PDAC risk including inherited genetic and non-genetic factors. Statement of Significance To understand how genetic variation contributes to PDAC risk in Black people in North American, we studied individuals of genetically-inferred African ancestry. We identified novel risk loci and differences in the contribution of known loci. This demonstrates that ancestry-informed genetic analyses improve our understanding of PDAC risk and enhances discovery.
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Drilon, Alexander E., Cho, B , Camidge, D Ross, Nagasaka, Misako, Besse, Benjamin, Solomon, B, Goto, Koichi , Wolf, Jürgen, Popat, Sanjay , Felip, Enriqueta, Yang, Nong, Langen, A. de, Lu, Shun, Velcheti, Vamsidhar, Lin, Andrew , Calvet, C. , Tschaika, Marina, Afsar, Salman, Yang, Haisu, Lin, Jessica J., Solomon, Benjamin , Cho, Byoung Chul , Besse, Benjamin , Drilon, Alexander , Langen, Adrianus J. de , Drilon, Alexander , Nagasaka, Misako , Besse, Benjamin , de Langen, Adrianus Johannes , Lin, Andrew L , Popat, Sanjay , Solomon, Benjamin J , Camidge, David Ross , Wolf, Jürgen , Felip, Enriqueta , Yang, Nong, Velcheti, Vamsidhar , Afsar, Salman

Mayo Clinic

The Oncologist | April 14, 2026 | Volume: 31 | Issue: 6 | Pages: No page available

10.1093/oncolo/oyag137 | PMID 41992489 Get It

Abstract Background Repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor, is approved for ROS1 fusion-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. Its side effects and safety management strategies require further characterization. Patients and Methods The safety profile of repotrectinib (treatment-emergent/related adverse events [TEAEs/TRAEs]) was established in patients who initiated treatment at the recommended dose (160 mg daily [QD] for 14 days, then 160 mg twice daily [BID]) across all cohorts of the global, multicenter phase 1/2 TRIDENT-1 study. AE management strategies were outlined. Results In 472 patients, the most common TRAEs (dizziness [58%] and dysgeusia [50%]) were likely TRK inhibition-related. Median relative dose intensity was 90%; 14% (n = 66/472) of patients did not increase their initial QD dose to BID (mostly due to CNS AEs). Rates of dizziness (median onset, 7 days) were similar in patients with/without baseline brain metastases. Dose modifications downgraded severity or resolved dizziness in 78% of patients; 58% of patients had pharmacologic intervention without dose modification. Dizziness was downgraded/resolved in 62% (n = 120/195) of patients who did not receive dose modification or pharmacologic intervention. Treatment-related cognitive impairment and weight gain occurred in 19% and 12% of patients, respectively. Treatment-emergent withdrawal pain occurred in 14% of patients (median resolution time, 2.1 weeks). Dose interruption and reduction from TRAEs occurred in 39% and 38% of patients, respectively; 10% reported later re-escalation back to 160 mg BID. Conclusion Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.
Abstract 2382: Achieving prostate cancer equity globally: Multinational advances from the iCCaRE consortium
Odedina, Folakemi T., Merriweather, Arnold, Dronca, Roxana , Colon-Otero, Gerardo, Popoola, Ademola Alabi, Asiedu, Gladys B. , Bolajoko, Opeyemi , COBRAN, Ewan, Asto-Flores, Emelina , Willis, Floyd B. , Williams, Christopher, Albertie, Monica, Fudge, Michelle, Toye, Oluwaseyi, Mahin, Collisa, Melton, J. Joseph, Kaninjing, Ernest , Rotimi, Solomon O. , Ashing, Kimlin , Popoola, Ademola , Cobran, Ewan K. , Williams, Christopher, Fudge, Michelle , Toye, Oluwaseyi

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2382-2382

10.1158/1538-7445.am2026-2382 Get It

Abstract Background: Black men across the African Diaspora experience a disproportionate burden of prostate cancer (CaP). The Inclusive Cancer Care Research Equity (iCCaRE) Consortium aims to eliminate CaP burden through global scientific collaboration, innovative research, community-engaged interventions, and next-generation workforce development. The primary objective for this Consortium was to optimize CaP diagnosis, treatment, and survivorship through research, research training and education, community engagement and community outreach. The Consortium integrates digital health technologies, community navigation, precision communication and precision science. Methods: Five full projects and one pilot project were launched across partner institutions in North America and Africa. Supported by multiple cores and services, the research activities included (1) implementation of a Point of Prostate Cancer Diagnosis Virtual Robot Assistant (PPCD-ViRA); (3) initiation of a cancer care at home trial; (4) migrant health studies of Caribbean and Sub-Saharan African immigrants; (5) expansion of genomic and metabolomic research; and (6) digital, psychosocial, and survivorship intervention development. Training and dissemination activities were deployed through iCCaRE TV, webinars, and community engagement programs including the Global Prostate Health Dialogue (Glo-PHD). Results: In one year, accomplishments included 45 presentations, 17 publications, 16 grant submissions, and 3 awards. The consortium delivered 408 live webinar engagements and reached more than 400 men globally through Glo-PHD. PPCD-ViRA was fully developed and prepared for clinical deployment (see https://www.youtube.com/watch?v=1mI-HS5R6sk). The African cohort expansion for genomic and metabolomic profiling was activated across several countries, with biospecimen collection underway. Media dissemination generated more than 15,000 views across platforms, including high-impact educational videos (see: www.youtube.com/@iCCaREConsortium). Training achievements included 13 early-career investigators and 7 trained prostate cancer advocates. Conclusions: In just one year, the iCCaRE Consortium Phase 2 made substantial progress toward transforming CaP equity globally. Through multidisciplinary science, digital innovation, and community partnerships, the consortium is building scalable infrastructure to address diagnosis experiences, treatment quality, and survivorship among Black men. Ongoing efforts will continue to advance precision medicine, culturally grounded interventions, and global capacity building. Citation Format: Folakemi T. Odedina, Arnold Merriweather, Roxana S. Dronca, Ernest T. Kaninjing, Solomon Rotimi, Gerardo Colon-Otero, Kimlin Ashing, Ademola A. Popoola, Gladys Asiedu, Opeyemi Bolajoko, Ewan COBRAN, Emelina Asto-Flores, Floyd Willis, Christopher Williams, Monica L. Albertie, Michelle Fudge, Oluwaseyi Toye, Collisa Mahin, Jada Melton, Inclusive Cancer Care Research Equity (iCCaRE) Consortium, Prostate Cancer Transatlantic Consortium (CaPTC). Achieving prostate cancer equity globally: Multinational advances from the iCCaRE consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2382.
Abstract 6289: Targeted sequencing of common cancer susceptibility genes reveals germline variants in African prostate cancer patients.
Onyia, Abimbola F. , Okwuchi, Freeman, Divine, Sylvester, Olasehinde, Olutola Esther, Yahaya, Ayinde, Salako, A A, Zakari, Aminu, Bassey, Iya, Petershie, Bernard, GANDAHO, Isidore, Brun, Luc, Sanni, Tore, Coulibaly, Sidi, Coulibaly, Noel, Fakayode, Michael, Issoufou, Coulibaly, Gbonon, Valérie Mbengue, Benjamin, Kouamé, Evrard, Yao, Coleman, Peter, Ajumbo, Victor, Wattanga, Lilac, Nyambega, Benson Ochieng, Odedina, Folakemi T., Campos, Opeyemi Christianah De , Titiloye, Nicholas Akinwale , Gandaho, Isidore, Noel, Coulibaly, Fakayode, Michael Karington , Kouame, Benjamin , Cassell, Ayun , Nyambega, Benson , Rotimi, Solomon O.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6289-6289

10.1158/1538-7445.am2026-6289 Get It

Abstract Background: Prostate cancer (PCa) is the leading cause of cancer-related deaths globally and disproportionately affects men of African ancestry. African men often present at younger ages and with more aggressive disease, and approximately half of the PCa risk has been attributed to genetic factors. Africa is the most genetically diverse region of the world, and even within the continent, populations show important differences in allele frequencies and patterns of pathogenic variation. Despite this diversity, African men remain underrepresented in genomic studies, creating significant gaps in knowledge that limit precision medicine efforts. Methods: A total of 182 prostate cancer patients were recruited from teaching hospitals in Benin, Côte d’Ivoire, Ghana, Kenya and Nigeria. 50 cancer susceptibility genes using the Aviseq ONCO50 panel and the Illumina MiSeq platform. Variant calling was performed using an in-house Snakemake workflow, followed by additional bioinformatic steps to distinguish true PMS2 variants from PMS2CL-related artifacts. Pathogenicity assessment relied on annotations from ClinVar and LOVD databases. Results: Pathogenic and likely pathogenic variants were detected in 31.3% of the study group identified in 26 genes. The five most frequently altered genes were RAD50, PTCH1, MSH6, MUTYH, and NF1. Nigerian patients accounted for 52.6 percent of all pathogenic variants, with recurrent alterations observed in MSH6, MUTYH, NF1, and PTCH1. In contrast, pathogenic BRCA1 and BRCA2 variants were observed primarily in patients from Kenya, Benin, and Côte d’Ivoire. Several frameshift, nonsense, and splice-site variants identified in this study have not been previously reported in African populations.[SR1] Conclusion: This study provides one of the most detailed assessments of inherited cancer susceptibility gene variants in African PCa patients. The findings reveal substantial regional variation in the spectrum of pathogenic variants and highlight population-specific genomic signatures that may contribute to the unequal burden of PCa in men of African ancestry. These data emphasize the importance of expanding genomic research efforts within Africa to strengthen precision oncology and reduce global PCa disparities. Citation Format: Abimbola F. Onyia, Freeman Okwuchi, Opeyemi C. De Campos, Sylvester Divine, Olutola Olasehinde, Ayinde Yahaya, Ayo Salako, Aminu Zakari, Iya Bassey, Nicholas Titiloye, Bernard Petershie, Isidore GANDAHO, Luc Brun, Tore Sanni, Safiatou Coulibaly, Noel Coulibaly, Michael Fakayode, Coulibaly Issoufou, Valérie Gbonon, Kouame Benjamin, Yao Evrard, Peter Coleman, Ayun Cassell, Victor Ajumbo, Lilac Wattanga, Benson Ochieng Nyambega, Folakemi T. Odedina, Solomon Rotimi. Targeted sequencing of common cancer susceptibility genes reveals germline variants in African prostate cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6289.
Integrative screening identifies functional variants and VNTRs underlying GWAS signals at the 5p15.33 multi-cancer susceptibility locus
O’Brien, Aidan , Kong, Hyunkyung, Patel, Harsh , Ho, Michelle , Patel, Minal, Zhong, Jun , Xu, Mai, Papenberg, Brenen W. , Connelly, Katelyn E. , Collins, Irene , Hennessey, Rebecca C. , Thakur, Rohit , Sowards, Hayley , Funderburk, Karen, Luong, Thong Minh, Florez-Vargas, Oscar , Myers, Timothy , Jermusyk, Ashley , Gorman, Bryan, Das, Sudipto, (PanScan/PanC4), The Pancreatic Cancer Cohort and Case-Control Consortia, Lan, Qing, Rothman, Nathaniel , McKay, James , Hung, R., Iles, Mark M. , Landi, Maria Teresa , Stolzenberg-Solomon, Rachael Z, Wolpin, Brian M. , Hassan, Manal M. , Antwi, Samuel O. , Lindström, Sara , Stern, Marc-Henri, Andrésson, Þorkell , Shi, Jianxin , Choi, Jiyeon, Brown, Kevin M, Rabe, Kari G. , Patel, Minal B , Hennessey, Rebecca , Luong, Thong , Jones, Kristine , Das, Sudipto , McKay, James , Hung, Rayjean J , Amos, Christopher I , Iles, Mark M , Koutros, Stella , Landi, Maria T , Law, Matthew H , Hassan, Manal M , Klein, Alison P , Orr, Nick , Chanock, Stephen Jacob , Lindstrom, Sara , Hoskins, Jason W , Shi, Jianxin , Prokunina-Olsson, Ludmila , Choi, Jiyeon , Brown, Kevin M , Amundadottir, Laufey , Chaffee, Kari G. , Antwi, Samuel O , Zhong, Jun , Luo, Wen , Lan, Qing , Rothman, Nathaniel , Amos, Christopher I. , Koutros, Stella , Law, Matthew H. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Orr, Nick , Hoskins, Jason W. , Stern, Marc‐Henri , Choi, Jiyeon , Ámundadóttir, Laufey T.

Mayo Clinic

No container title available | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.03.26347427 | PMID 41867231 Get It

Abstract Chromosome 5p15.33 harbors several independent association signals which demonstrate antagonistic pleiotropy across cancer types, with causal mechanisms largely unresolved. To identify functional variants and enhancer elements at this locus, we performed statistical fine-mapping followed by massively parallel reporter assays (MPRA) and proliferation based CRISPRi screens. This approach identified eight multi-cancer functional variants (MCFVs) across three GWAS signals. Targeting rs421629 (part of the CLPTM1L signal marked by rs465498) with CRISPRi revealed opposing effects on TERT expression in pancreatic versus lung cancer cells, consistent with the antagonistic pleiotropy observed for this signal. Furthermore, CRISPRi nominated an intronic CLPTM1L variable number tandem repeat (VNTR) as a potent enhancer. Long-read sequencing established VNTR polymorphisms as potential causal variants for the rs465498 signal. We showed that Hippo-pathway transcription factors mediate VNTR enhancer activity in lung and pancreatic cancer cells. Together, these findings indicate that cancer susceptibility at 5p15.33 may be mediated by both SNPs and VNTRs and provide an integrated framework for resolving complex pleiotropic loci.